Cheng Fang
Tracked across 1 events · 6 articles · First seen Aug 14, 2026 · Last active Aug 14, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Annovis Bio, Inc. (NYSE: ANVS) announced on August 14, 2026, that its pivotal Phase 3 Alzheimer's disease (AD) trial has reached full enrollment with 850 patients, exceeding the original target of 760. The trial evaluates…
Impact: Cheng Fang was promoted to Chief Scientific Officer, a move that strengthens the company's scientific leadership as it approaches key regulatory milestones. This promotion signals continuity and expertise in clinical execution.
Aug 14, 2026 · 6 articles
40
Annovis Bio promoted Cheng FangAnnovis Bio Phase 3 AD...
ERGEN INTELLIGENCE
Track Cheng Fang live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard